Expression of dengue capsid-like particles in silkworm and display of envelope domain III of dengue virus serotype 2
- PMID: 38971211
- DOI: 10.1016/j.pep.2024.106543
Expression of dengue capsid-like particles in silkworm and display of envelope domain III of dengue virus serotype 2
Abstract
Dengue virus (DENV) is a considerable public health threat affecting millions of people globally. Vaccines for dengue are an important strategy to reduce the disease burden. We expressed capsid (C2) and envelope domain III of dengue virus serotype 2 (2EDIII) separately in the silkworm expression system. We conjugated them employing the monomeric streptavidin (mSA2) and biotin affinity to display the antigenic 2EDIII on the C2-forming capsid-like particle (CLP). Purified 2EDIII-displaying C2 (CLP/2EDIII) was immunogenic in BALB/c mice, eliciting neutralizing antibodies confirmed by a single-round infectious particle (SRIP) neutralization assay. Th1 cytokine levels were upregulated for the CLP/2EDIII group, and the anti-inflammatory IL-10 and pro-inflammatory IL-6 cytokine levels were also raised compared to the 2EDIII and the control groups. Elevated cytokine levels for CLP/2EDIII indicate the importance of displaying the 2EDIII as CLP/2EDIII rather than as an individual subunit. This study is the first to express the C2 protein as self-assembling CLP in vivo and 2EDIII separately in the silkworm expression system and conjugate them to form a monovalent CLP. Thus, this CLP/2EDIII display method may pave the way for an efficient tetravalent dengue vaccine candidate.
Keywords: Capsid-like particle; Dengue; Envelope domain III; Silkworm; Vaccine; Virus-like particle.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest All the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Tetravalent Virus-like Particles Engineered To Display Envelope Domain IIIs of Four Dengue Serotypes in Silkworm as Vaccine Candidates.Biomacromolecules. 2025 Mar 10;26(3):2003-2013. doi: 10.1021/acs.biomac.4c01831. Epub 2025 Feb 3. Biomacromolecules. 2025. PMID: 39895207
-
A tetravalent dengue vaccine containing a mix of domain III-P64k and domain III-capsid proteins induces a protective response in mice.Arch Virol. 2014 Oct;159(10):2597-604. doi: 10.1007/s00705-014-2115-2. Epub 2014 May 20. Arch Virol. 2014. PMID: 24841761
-
An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.J Virol. 2017 Nov 14;91(23):e01181-17. doi: 10.1128/JVI.01181-17. Print 2017 Dec 1. J Virol. 2017. PMID: 28956764 Free PMC article.
-
Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.BMC Biotechnol. 2016 Jun 14;16(1):50. doi: 10.1186/s12896-016-0280-y. BMC Biotechnol. 2016. PMID: 27301568 Free PMC article.
-
A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.Expert Rev Vaccines. 2016;15(4):497-508. doi: 10.1586/14760584.2016.1128328. Epub 2016 Feb 22. Expert Rev Vaccines. 2016. PMID: 26635182 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous